AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca consolidated Total Revenue ($M) ($M)
Form 20-F & Form 6-K Consolidated Statement of Comprehensive Income (Postgres DB + Form 6-K Backfill)
Latest, FY2025
58,739
Period ended Dec 31, 2025
Change on a year earlier
+8.6%
54,073 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Consolidated Total Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 58,739 | +8.6% | Form 20-F (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 54,073 | +18.0% | Form 20-F (filed 2025-02-18) ↗ |
| FY2023 | Dec 31, 2023 | 45,811 | +3.3% | Form 20-F (filed 2024-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 44,351 | +18.5% | Form 20-F (filed 2023-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 37,417 | +40.6% | Form 20-F (filed 2022-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 26,617 | +9.2% | Form 20-F (filed 2021-02-16) ↗ |
| FY2019 | Dec 31, 2019 | 24,384 | +10.4% | Form 20-F (filed 2020-03-03) ↗ |
| FY2018 | Dec 31, 2018 | 22,090 | -1.7% | Form 20-F (filed 2019-03-05) ↗ |
| FY2017 | Dec 31, 2017 | 22,465 | -2.3% | Form 20-F (filed 2018-03-06) ↗ |
| FY2016 | Dec 31, 2016 | 23,002 | -6.9% | Form 20-F (filed 2018-03-06) ↗ |
| FY2015 | Dec 31, 2015 | 24,708 | – | Form 20-F (filed 2018-03-06) ↗ |
Breakdown
What makes up consolidated total revenue ($m)
- Cost of sales ($M)10,633 · FY2025
- Gross profit ($M)48,106 · FY2025
- Distribution expense ($M)579 · FY2025
- Research and development expense ($M)14,232 · FY2025
- Selling, general and administrative expense ($M)19,933 · FY2025
- Other operating income and expense ($M)381 · FY2025
- Operating profit ($M)13,743 · FY2025
- Net finance expense ($M)-1,334 · FY2025
- Finance income ($M)360 · FY2025
- Finance expense ($M)1,694 · FY2025
- Share of after-tax losses of associates and joint ventures ($M)-7 · FY2025
- Profit before tax ($M)12,402 · FY2025
- Taxation ($M)2,169 · FY2025
- Profit for the period / Net income ($M)10,233 · FY2025
- Profit attributable to owners of the Parent ($M)10,225 · FY2025
- Basic earnings per $0.25 Ordinary Share ($)6.60 · FY2025
- Diluted earnings per $0.25 Ordinary Share ($)6.54 · FY2025
- Dividends declared per Ordinary Share ($)3.13 · FY2025
- Weighted average basic shares outstanding (millions)1,550 · FY2025
- Weighted average diluted shares outstanding (millions)1,562 · FY2025
Cite this data
StockData. (2026). AstraZeneca Consolidated Total Revenue ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/fin_rev
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.